Some have relabeled it as Pentadecapeptide Aringate or PDA (changing the acetate to an arginate) and are prescribing it for subcutaneous administration that way, while the confusion about its status has led to a vibrant oral capsule market for BPC in what appears to be a grey area of legality
Someone is losing weight on semaglutide or tirzepatide, the rate has slowed around month four, and they want to add AOD-9604 to push past a plateau
A once-daily trial schedule does not prove once daily is best for every cosmetic, and a twice-daily cosmetic label does not prove twice daily is superior
06 Verify clarity The solution should be clear and colorless
Below is a general timeline based on common clinical experience and published research, with the reminder that individual responses vary
If theyre still stumped, they may recommend additional testing to rule out other causes